Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
Read more
10
December 2024
Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to ‘Watchful Waiting’
Read more
13
November 2024
Enterome to host webinar on new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of lead programme, EO2463
Read more
06
November 2024
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
Read more
05
November 2024
Enterome to Present Immunotherapy Pipeline Updates at Upcoming Investor Meetings
Read more
11
June 2024
Enterome to Present Data on OncoMimics™ Approach to Cancer Immunotherapy at EACR 2024
Read more
24
May 2024
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
Read more
25
April 2024
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more
17
April 2024
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
